The analysis showed ICC patients with strong SALL4-positive levels (+++) had poorer prognosis than patients with moderate SALL4-positive levels (++) (P = 0.0471), weak SALL4-positive levels (+) (P = 0.014), and SALL4-negative expression (−) (P = 0.0055) (Figure 2). The gene discussed is SALL4; the disease is intrahepatic cholangiocarcinoma.